Home›Research›Compare›Cagrilintide vs Retatrutide
Peptide ComparisonCagrilintide vs Retatrutide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
19 providers listed
Retatrutide
LY3437943
Half-life: ~6 days
94 providers listed
Cagrilintide carries stronger published evidence (Meta-analysis, 10 key studies) than Retatrutide (RCT, 13); both are research compounds.
Cagrilintide
Evidence
Half-life
~7 days
Retatrutide
Evidence
Half-life
~6 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Cagrilintide |
| Lower typical price per mg | Retatrutide |
| More provider options (19 vs 94) | Retatrutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cagrilintide
Retatrutide
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+6 more
Retatrutide
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Beyond weight loss: multisystem benefits of obesity medications.
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
+9 more
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Retatrutide
Class-based (investigational)
Cagrilintide
Retatrutide
Where to source these peptides
Cagrilintide
19 listed
Browse directory →
Providers offeringRetatrutide
94 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Retatrutide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/retatrutide